|
Paclitaxel Albumin-stabilized Nanoparticle Formulation This page contains brief information about paclitaxel albumin-stabilized nanoparticle formulation and a collection of links to more information from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA). | US Brand Name(s): |  | Abraxane | | | | FDA Approved: | | Yes |
Paclitaxel Albumin-stabilized Nanoparticle Formulation is approved by the Food and Drug Administration (FDA) to treat metastatic and recurrent breast cancer. The drug is also called nanoparticle paclitaxel and protein-bound paclitaxel. Nanoparticle paclitaxel causes fewer side effects than paclitaxel. Nanoparticle paclitaxel is also being studied in the treatment of other types of cancer. Information from the FDA
FDA Approval for Paclitaxel Albumin-stabilized Nanoparticle Formulation - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: New Form of Paclitaxel Causes Fewer Side Effects (10/17/2005) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical TrialsClinical Trials for Paclitaxel Albumin-stabilized Nanoparticle Formulation - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
 Back to Top |
